StockData
Reviva Pharmaceuticals Holdings, Inc. logo

Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock

RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 2/30
$0.45−0.02 (-4.36%)

Close on Oct 19, 2026Market cap $5.94MP/E –Yield –

Reviva Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Reviva Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$13.90M. For fiscal 2025 it was -$24.59M. The highest annual figure on record is -$218.44K in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$24.59M–
FY2024Dec 31, 2024-$33.54M–
FY2023Dec 31, 2023-$28.32M–
FY2022Dec 31, 2022-$18.96M–
FY2021Dec 31, 2021-$10.67M–
FY2020Dec 31, 2020-$4.07M–
FY2019Dec 31, 2019-$218.44K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.18M–
Q2 FY2026Jun 30, 2026-$2.12M–
Q1 FY2026Mar 31, 2026-$3.80M–
Q4 FY2025Dec 31, 2025-$5.80M–
Q3 FY2025Sep 30, 2025-$5.59M–
Q2 FY2025Jun 30, 2025-$5.01M–
Q1 FY2025Mar 31, 2025-$8.19M–
Q4 FY2024Dec 31, 2024-$9.10M–
Q3 FY2024Sep 30, 2024-$4.24M–
Q2 FY2024Jun 30, 2024-$8.48M–
Q1 FY2024Mar 31, 2024-$11.73M–
Q4 FY2023Dec 31, 2023-$8.88M–
Q3 FY2023Sep 30, 2023-$6.18M–
Q2 FY2023Jun 30, 2023-$5.32M–
Q1 FY2023Mar 31, 2023-$7.95M–
Q4 FY2022Dec 31, 2022-$4.69M–
Q3 FY2022Sep 30, 2022-$4.00M–
Q2 FY2022Jun 30, 2022-$4.00M–
Q1 FY2022Mar 31, 2022-$6.27M–
Q4 FY2021Dec 31, 2021-$3.90M–
Q3 FY2021Sep 30, 2021-$2.31M–
Q2 FY2021Jun 30, 2021-$1.34M–
Q1 FY2021Mar 31, 2021-$3.12M–
Q2 FY2018Aug 31, 2018-$92.35K–

More Reviva Pharmaceuticals figures

See a number that looks wrong?